Christine Olson

Jun 6, 2024 | biorxiv.org | Kai Trepka |Than kyaw |Christine Olson |Wesley A Kidder

AbstractDose-limiting toxicities remain a major barrier to drug development and therapy, revealing the limited predictive power of human genetics. Herein, we demonstrate the utility of a more comprehensive approach to studying drug toxicity through longitudinal study of the human gut microbiome during colorectal cancer (CRC) treatment ( NCT04054908) coupled to cell culture and mouse experiments.